Genetic polymorphism, medical therapy and sequential cardiac function in patients with heart failure;Polimorfismo genético, terapia farmacológica e função cardíaca seqüencial em pacientes com insuficiência cardíaca

Arquivos Brasileiros de Cardiologia

Volumn 90, Issue 4, 2008, Pages

  Cuoco, Marco Antonio Romeo ^a,b   Pereira, Alexandre Costa ^a   Da Mota, Glória De Fátima Alves ^a   Krieger, José Eduardo ^a   Mansur, Alfredo José ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Angiotensin converting enzyme inhibitors; Genetics; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ACE GENE; ADULT; ALLELE; ARTICLE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GENE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

EID: 44849124626     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2008000400007     Document Type: Article

References (23)

1. Sasaki M, Oki T, Iuchi A, Tabata T, Yamada H, Manabe K, et al. Relationship between the angiotensin converting enzime gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens. 1996; 14: 1403-8.
2. McNamara DM, Holubkov R, Janosko K, Palmer A, Wang JJ, MacGowan GA, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation. 2001; 103: 1644-8.
3. McNamara DM, Holubkov R, Postava L, Janosko K, MacGowan GA, Mathier M, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol. 2004; 44: 2019-26.
4. Cicoira M, Rossi A, Bonapace S, Zanolla L, Perrot A, Francis DP, et al. Effects of ACE gene insetion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. Am J Med. 2004; 116: 657-61.
5. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86: 1343-6.
6. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin-converting enzyme gene (DCP1) (dipeptidylcarboxypeptidase 1). Nucleic Acids Res. 1992; 20: 1433.
7. Andersson B, Sylvén C. The DD genotype of the angiotensin- converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol. 1996; 28: 162-7.
8. Cuoco MAR, Pereira AC, Freitas HFG, Mota GFA, Fukushima JT, Krieger JE, et al. Angiotensin-converting enzyme gene deletion polymorphism modulation of onset of symptoms and survival rate of patients with heart failure. Int J Cardiol. 2005; 99: 97-103.
9. Mckee PA, Castelli WP, Mcnamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971; 285: 1441-6.
10. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J. 1980; 44: 672-3.
11. Richardson P, Mckenna W, Bristow M, Maisch B, Mautner B, O'connel J, et al. Report of the 1995 World Health Organization Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation. 1996; 93: 841-2.
12. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991; 325: 293-302.
13. Sahn DJ, De Maria A, Kisslo J, Weyman A. The committee on M-mode standardization of the American Society of Echocardiography. Circulation. 1978; 58: 1072-83.
14. Miller AS, Dykes DD, Polesky HF. A single salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16: 1215.
15. Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR Methods Appl. 1993; 3: 120-1.
16. Lindpainter K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, Lamotte F, et al. A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med. 1995; 332: 706-11.
17. SAS Institute Inc, SAS/STAT® User's Guide. Version 6. Cary, North Caroline: SAS Institute Inc; 1989.
18. Danser AHJ, Schalekamp MADH, Bax WA, Brink AM, Saxena PR, Rieger GAJ, et al. Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation 1995;92:1387-8.
19. Ueda S, Elliot HL, Morton JJ, Connell JMC. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension. 1995; 25: 1266-9.
20. Ueda S, Meredith PA, Morton JJ, Connell JMC, Elliot HL. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (Enalaprilat) in humans. Circulation. 1998; 98: 2148-53.
21. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316: 1429-35.
22. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation. 1993 (Suppl VI):VI-40-VI-48.
23. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al, for the Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004; 25: 292-9.